Home
>
US Stocks
>
APPLIED MOLECULAR TRANSPORT

APPLIED MOLECULAR TRANSPORT (AMTI)

$0.26

-0.01

(-2.33%)▲

Live

Insights on APPLIED MOLECULAR TRANSPORT

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 136.9%

Performance

  • $0.26
    $0.28
    $0.26
    downward going graph

    1.15%

    Downside

    Day's Volatility :9.32%

    Upside

    8.26%

    downward going graph
  • $0.21
    $4.17
    $0.26
    downward going graph

    19.04%

    Downside

    52 Weeks Volatility :94.95%

    Upside

    93.76%

    downward going graph

Returns

PeriodAPPLIED MOLECULAR TRANSPORTSector (Health Care)Index (Russel 2000)
3 Months
-57.13%
0.7%
-6.8%
6 Months
-73.38%
-8.3%
-6.0%
1 Year
-91.04%
-1.9%
-4.6%
3 Years
-98.52%
25.3%
25.9%

Highlights

Market Capitalization
10.1M
Book Value
$0.92
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.81
Wall Street Target Price
0.6
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-47.68%
Return On Equity TTM
-136.19%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-42.1M
EBITDA
-98.2M
Diluted Eps TTM
-2.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.09
EPS Estimate Next Year
-0.88
EPS Estimate Current Quarter
-0.6
EPS Estimate Next Quarter
0.06

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 8 Wall street analysts offering stock ratings for APPLIED MOLECULAR TRANSPORT(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
1
Hold
4
5
5
Sell
4
5
4

Analyst Forecast

What analysts predicted

Upside of 130.77%

Current $0.26
Target $0.60

Technicals Summary

Sell

Neutral

Buy

APPLIED MOLECULAR TRANSPORT is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
APPLIED MOLECULAR TRANSPORT
APPLIED MOLECULAR TRANSPORT
0.8%
-73.38%
-91.04%
-98.52%
-98.52%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
APPLIED MOLECULAR TRANSPORT
APPLIED MOLECULAR TRANSPORT
NA
NA
NA
-1.09
-1.36
-0.48
0.0
0.92
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
APPLIED MOLECULAR TRANSPORT
APPLIED MOLECULAR TRANSPORT
Sell
$10.1M
-98.52%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • EPIQ Capital Group, LLC

    22.24%

  • Founders Fund V Management, LLC

    9.21%

  • Vanguard Group Inc

    3.45%

  • Founders Fund VI Management, LLC

    2.11%

  • BlackRock Inc

    1.51%

  • LAURION CAPITAL MANAGEMENT LP

    1.23%

Corporate Announcements

  • APPLIED MOLECULAR TRANSPORT Earnings

    APPLIED MOLECULAR TRANSPORT’s price-to-earnings ratio stands at None

    Read More

Company Information

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT's proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell's own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease. AMT's headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA.

Organization
APPLIED MOLECULAR TRANSPORT
Employees
15
CEO
Mr. Graham K. Cooper
Industry
Health Technology

Discover More

FAQs